About Econic Biosciences
Econic Biosciences is a company based in London (United Kingdom) founded in 2022 by Richard Koche and Shaun Foy. Econic Biosciences has raised $19.97 million across 3 funding rounds. Econic Biosciences offers products and services including ecDNA Targeting Therapies. Econic Biosciences operates in a competitive market with competitors including Noetik, Function Oncology, Meliora Therapeutics, Transition Bio and Alixia, among others.
- Headquarter London, United Kingdom
- Founders Richard Koche, Shaun Foy
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Econic Biosciences Limited
- Date of Incorporation 17 Dec, 2021
- Jurisdiction LONDON, ENGLAND
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$19.97 M (USD)
in 3 rounds
-
Latest Funding Round
$4.93 M (USD), Series B
May 16, 2024
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Econic Biosciences
Econic Biosciences offers a comprehensive portfolio of products and services, including ecDNA Targeting Therapies.
Develops drugs targeting extrachromosomal DNA for cancer therapy
People of Econic Biosciences
Unlock access to complete
Senior Team
2 people
Operations Team
1 people
Scientist Team
1 people
Leadership Team
1 people
Principal Team
1 people
Unlock access to complete
Funding Insights of Econic Biosciences
Econic Biosciences has successfully raised a total of $19.97M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $4.93 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by Econic Biosciences
Investment portfolio details for Econic Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Econic Biosciences
Detailed financials for Econic Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Econic Biosciences Comparisons
Peer comparison for Econic Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Econic Biosciences
Econic Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Noetik, Function Oncology, Meliora Therapeutics, Transition Bio and Alixia, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Cancer immunotherapies are discovered and developed via AI platform.
|
|
| Locked | Locked | Locked |
Cancer therapeutics are developed using a CRISPR-enabled platform.
|
|
| Locked | Locked | Locked |
Machine learning-driven platform for oncology drug discovery is offered.
|
|
| Locked | Locked | Locked |
Technology platform for biomolecular condensate analysis is developed.
|
|
| Locked | Locked | Locked |
Cancer drug discovery platform is provided for tumor mutation targeting.
|
|
| Locked | Locked | Locked |
Web-based solutions for genomic testing and sequencing access are provided.
|
Detailed competitors of Econic Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Econic Biosciences
Complete news archive for Econic Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Econic Biosciences
Econic Biosciences was founded in 2022.
Econic Biosciences is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Econic Biosciences is a funded company, having raised a total of $19.97M across 3 funding rounds to date.
Econic Biosciences was founded in 2022 in London, United Kingdom, within the biotechnology sector. A platform is developed for the discovery and development of targeted cancer therapies. AI is employed to identify and characterize ecDNA, a mediator of oncogenic gene amplification and driver of tumor evolution. Development of therapies specifically targeting ecDNA is enabled to address needs of cancer patients.
Econic Biosciences's top competitors include Noetik, Transition Bio and Function Oncology.
Econic Biosciences offers ecDNA Targeting Therapies.